Medical linear accelerator market seen hitting $6 billion by 2030

The medical linear accelerator market is projected to grow from $4.35 billion in 2026 to $6 billion by 2030, driven by rising cancer cases, more precise radiotherapy tools and broader hospital investment. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Medical linear accelerators are a core tool in radiation therapy, helping doctors target tumors while limiting harm to healthy tissue. - Rising cancer incidence is pushing demand for more precise treatment systems and expanded oncology capacity. - The market’s growth points to continued investment in cancer care infrastructure, treatment technology and research centers.

What happened: - The Business Research Company released its Medical Linear Accelerator Market Report 2026, covering market size, trends and global forecasts for 2026-2035. - The report says the market will grow from $4 billion in 2025 to $4.35 billion in 2026. - The report projects the market will reach $6 billion by 2030. - The report estimates an 8.7% CAGR in the historical period and an 8.4% CAGR through 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region in the coming years.

The details: - Growth in the historical period was linked to limited access to advanced radiotherapy, continued reliance on traditional low-energy linacs, rising cancer cases, hospital and clinic expansion, and basic image-guided therapy adoption. - Future growth is expected to be supported by high-precision linac systems, broader use of stereotactic and proton therapies, higher spending on cancer treatment facilities, more AI and data analytics in radiotherapy, and more oncology and radiation therapy research centers. - The report highlights rising adoption of advanced radiation therapy techniques, greater demand for high-energy linear accelerators, more dedicated linac installations, increased focus on pediatric and skin cancer treatments, and wider use of image-guided and stereotactic therapies. - The report defines a medical linear accelerator as a radiation therapy device that delivers high-energy X-rays or electron beams to target cancerous tumors with precision. - The technology accelerates electrons using microwave technology and directs them at a targeted area to produce focused radiation. - The report says the device is important because it can destroy cancer cells while minimizing damage to surrounding tissue. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report’s 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, and updated graphics and tables. - The report cites the American Cancer Society’s January 2024 estimate of about 297,790 new invasive breast cancer cases in women diagnosed during 2023.

Between the lines: - The market outlook reflects a broader shift from basic radiation delivery toward more customized and data-driven cancer treatment. - Asia-Pacific’s expected growth suggests the biggest gains may come from healthcare modernization and expanded access, not just from mature markets replacing older systems. - The emphasis on AI, stereotactic therapy and high-precision systems signals a race to improve targeting accuracy and clinical outcomes.

What's next: - More hospitals and cancer centers are likely to invest in advanced linac systems as demand for radiotherapy rises. - Research activity around oncology and radiation therapy could accelerate adoption of image-guided and stereotactic treatment methods. - The market’s growth trajectory will likely keep pressure on providers to expand capacity and upgrade older equipment. - More information is available in the full medical linear accelerator market report and a free sample report.